Evidence map›Paper›PMID 27826643›Full record

ArticleEuropean journal of clinical pharmacology2017

Association between antithrombotic treatment and hemorrhagic stroke in patients with atrial fibrillation-a cohort study in primary care.

Per Wändell, Axel C Carlsson, Martin Holzmann, Johan Ärnlöv, Sven-Erik Johansson, Jan Sundquist, Kristina Sundquist

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Per WändellDivision of Family Medicine, Department of Neurobiology, Care Science and Society, Karolinska Institutet, Alfred Nobels Allé 12, 141 83, Huddinge, Sweden. per.wandell@ki.se.ORCID http://orcid.org/0000-0001-5169-2965
Axel C CarlssonDivision of Family Medicine, Department of Neurobiology, Care Science and Society, Karolinska Institutet, Alfred Nobels Allé 12, 141 83, Huddinge, Sweden.
Martin HolzmannDepartment of Emergency Medicine, Karolinska University Hospital, Stockholm, Sweden.
Johan ÄrnlövDepartment of Medical Sciences, Cardiovascular Epidemiology, Uppsala University, Uppsala, Sweden.
Sven-Erik JohanssonCenter for Primary Health Care Research, Lund University, Malmö, Sweden.
Jan SundquistCenter for Primary Health Care Research, Lund University, Malmö, Sweden.
Kristina SundquistCenter for Primary Health Care Research, Lund University, Malmö, Sweden.
Lund University · SEDalarna University · SEKarolinska Institutet · SEKarolinska University Hospital · SEUppsala University · SE

Funding

Neighborhoods and Coronary Disease: Exploring Mechanisms and Improving MethodsR01HL116381 · NHLBI · LUNDS UNIVERSITET · PI SUNDQUIST, KRISTINA · 2014 to 2017
$1.9M
NHLBI NIH HHS R01 HL116381
6 · The paper itself

Abstract

objectiveThe objective of this study was to study the association between antithrombotic treatment and risk of hemorrhagic stroke (HS) in patients with atrial fibrillation (AF) treated in primary health care.

methodsStudy population included all adults (n = 12,215) 45 years and older diagnosed with AF at 75 primary care centers in Sweden 2001-2007. Outcome was defined as a first hospital episode with a discharge episode of HS after the AF diagnosis. Association between HS and persistent treatment with antithrombotic agents (warfarin, acetylsalicylic acid (ASA), clopidogrel) was explored using Cox regression analysis, with hazard ratios (HRs) and 95 % CIs. Adjustment was made for age, socioeconomic status, and co-morbid cardiovascular conditions.

resultsDuring a mean of 5.8 years (SD 2.4) of follow-up, 162 patients (1.3 %; 67 women and 95 men) with HS were recorded. The adjusted risk associated with persistent warfarin treatment compared to no antithrombotic treatment consistently showed no increased HS risk, HR for women 0.53 (95 % CI 0.23-1.27) and for men 0.55 (95 % CI 0.29-1.04); corresponding HRs for ASA were, for women, 0.45 (95 % CI 0.14-1.44) and, for men, 0.56 (95 % CI 0.24-1.29).

conclusionsIn this clinical setting, we found no evidence pointing to an increased risk of HS with antithrombotic treatment.

Indexed as

AgedAged, 80 and overAnticoagulantsAspirinAtrial FibrillationClopidogrelCohort StudiesFemaleFibrinolytic AgentsHumansIntracranial HemorrhagesMaleMiddle AgedPlatelet Aggregation InhibitorsPrimary Health CareStrokeAnticoagulantsAspirinClopidogrelFibrinolytic AgentsPlatelet Aggregation InhibitorsTiclopidineWarfarinAnticoagulantsAtrial fibrillationCardiovascular co-morbidityGenderHemorrhagic strokeMortality

Identifiers

PMID27826643
PMCPMC5226983
OpenAlexW2555365093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.